Skip to main content

Branded

  • Tris Pharma launches Dyanavel XR
    MONMOUTH JUNCTION, N.J. — Tris Pharma announced this week that it had launched its Dyanavel XR (amphetamine) extended-release liquid for oral suspension. The drug is indicated to treat attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and older
     

  • Dr. Reddy’s subsidiary announces Zembrace SymTouch U.S. availability
    HYDERABAD, India. — Dr. Reddy’s Laboratories subsidiary Promius Pharma announced Tuesday that its Zembrace SymTouch (sumatriptan injection) is now commercially available in the United Stated. 
     
    The pre-filled, low-dose autoinjector contains 3 mg of sumatriptan, which can lead to rapid migraine relief. 
     

  • Adapt Pharma launches Narcan Now app
    DUBLIN — Adapt Pharma, maker of Narcan (naloxone) Nasal Spray announced Thursday the launch of its smartphone app Narcan Now. The app provides patients information about how to recognize the signs and symptoms of an opioid overdose, an instructional video and  a three-step administration guide for Narcan Nasal Spray, as well as emergency services access. 
     
    The app is available through the iTunes App Store for iOS devices and the Google Play store for Android devices. 
     

  • Biosimilars to save billions

    Zarxio (filgrastim-sndz), the first U.S. biosimilar

    Biologic medications — nine of which were among the Food and Drug Administration’s approvals in 2015 — constitute a big portion of the specialty market, and with the recent introduction of the first U.S. biosimilar, Zarxio (filgrastim-sndz), biologic makers are going to see a shakeup in the coming years as more biosimilars become available.

  • Specialty pharmacy drives prescription growth

    It’s no secret that the category of drugs drawing the most attention — and money — in recent years has been specialty pharmacy. And it shouldn’t be surprising that the growth the category has experienced in the past several years — pushed more recently by hepatitis C and oncology treatments — isn’t expected to slow anytime soon.

  • Congress passes Ensuring Patient Access Act
    ARLINGTON, Va. – The U.S. House of Representatives on Tuesday passed the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (S. 483) in the same version passed by the Senate, making President Obama’s consideration and signature the final step before enactment.
     
    The legislation, advocated by both retail pharmacy and the pharma industry, would advance collaboration among health and enforcement authorities to achieve drug abuse solutions that maintain patients’ legitimate access to medications.

  • New PBM SentinelRx launches
     
    DETROIT — New pharmacy benefit manager SentinelRx announced its launch on Tuesday, noting that it aims to create a custom pharmacy experience for customers through high transparency and personalized service. 
     
    The company said it uses web-based pharmacy benefit system MERLIN, which has 16 integrated modules that can aid in personalizing service for each client. It provides drug access through a network of more than 66,000 pharmacies in 50 states, Puerto Rico, Guam and the U.S. Virgin Islands. 

  • Accenture: Pharma companies to invest in patient-centered services, capabilities
    NEW YORK — A new report from Accenture is shedding light on a new focus on the part of pharmaceutical companies: investing in patient-centered capabilities and services. The report uses responses from 200 American and European pharma executives, 85% of whom said that their companies would be increasing its patient-centered capabilities in the next two years. 
     
X
This ad will auto-close in 10 seconds